Close Menu

stock rating

The eight firms for which Jefferies resumed coverage are Myriad Genetics, Cepheid, Gen-Probe, Complete Genomics, Exact Sciences, Genomic Health, Sequenom, and Nanosphere.

In addition to initiating coverage of Cepheid, Gen-Probe, Myriad Genetics, and Qiagen, the investment bank also began coverage of Alere and Hologic.

Despite the upgrade, an analyst expressed concern about the commercial value of the test, noting the cost involved.

Wedbush also placed a 12-month price target of $9 on Caliper's shares, saying that "new product traction in next-generation sequencing sample preparation as well as greater adoption of the company's products in molecular diagnostics can drive upside to consensus estimates."

The investment firm gave Illumina an "outperform" rating and an "aggressive growth" company profile.

In a research note, the investment house said that Caliper may be limited in its ability to exceed heightened expectations.

The company's stock took a hit after the investment firm downgraded it to "underweight" from "neutral."

R.W. Baird, the Cowen Group, Jefferies, and UBS each recommended Complete Genomics' stock with target share prices significantly above the company's current trading price.

The investment firm noted the "enormous" market opportunity for Exact Sciences' Cologuard test and predicted it would receive FDA clearance in 2013.

All of the banks issued favorable recommendations on the molecular diagnostics firm's stock.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.